

CordenPharma Switzerland is a cGMP manufacturer of advanced pharmaceutical intermediates and APIs, with particular focus on the production of small molecules, lipids, GalNac and carbohydrates. Located 15 km from Basel in Liestal, Switzerland, the facility was started in 1987 by Sygena AG before being purchased by Genzyme Pharmaceuticals in 1994. In 2011, the facility was acquired by ICIG and became Corden Pharma Switzerland LLC.

CordenPharma Switzerland brings over 30 years of experience and expertise in the pharmaceutical manufacturing arena with a particular focus on chemistry, technology and project management. The cGMP facility has been fully inspected by global regulatory agencies including, but not limited to, Swissmedic, FDA and PMDA (Japan).

APIs:

Clinical & Commercial API Support Services

Integrated Supply Drug Product Facilities:

CordenPharma Caponago (IT)
CordenPharma Plankstadt (DE)

Related Technology Platforms:





Lipids & Carbohydrates

Small Molecules



SWITZERLAND FACILITY FACTS

Core Capabilities

- » New process development and / or technology transfer for small molecules or lipids
- Manufacture of APIs, Standard Lipids & Advanced GMP Intermediates from gram-scale to multi-kilos
- Flexible, multi-purpose manufacturing plants with reactors up to 2,500 L
- On-site, comprehensive analytical development & QC facilities
- Wide range of chemical capability (hydrogenation, coupling chemistry & organometallics)
- CordenPharma Centre of Excellence for Small Molecule & Custom Lipid Chemical Development

Capacities / Technologies

- Reactors from 20 L to 2,500 L (Total Capacity - 27,000 L)
- Materials of construction: stainless steel, glass-lined & Hastelloy
- » Reactions conditions: -90°C to 160°C and 1mbar to 20bar (vacuum/pressure)
- Dryers: vacuum tray, filter & conical (also lyophilization)
- » Chromatographic capabilities from small to large-scale (SFC, HPLC & MPLC)



www.cordenpharma.com/facilities/liestal



www.cordenpharma.com/contact-us

